T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...

Daiichi Sankyo receives Prime Minister’s Award for Japan Medical Research and Development Grand Prize: Tokyo Tuesday, January 20, 2026, 17:00 Hrs [IST] Daiichi Sankyo has receiv ...

As we age, the immune system gradually declines in function, leaving the body more vulnerable to disease. Scientists have discovered a new way to rejuvenate a key component of immune function, ...

Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration  Scott ...

Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics ...